Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Axl(KPL-4 cells):109.7 pM

方法:Trastuzumab deruxtecan (T-DXd)(1 pM-10 nM,5天)处理HER2 阳性 KPL-4 细胞，计算细胞活力。
结果:Trastuzumab deruxtecan可以抑制 HER2 阳性 KPL-4 细胞的生长，IC50 值为 109.7 pM。[2]
方法:Trastuzumab deruxtecan (10nM，5天）处理共培养的HER2 阳性 KPL-4 细胞和 HER2 阴性 MDA-MB-468 细胞，测定活细胞的数量，确认其是否诱导旁观者杀伤作用。
结果:Trastuzumab deruxtecan同时杀死了 KPL-4 和 MDA-MB-468 细胞。[2]

方法:Trastuzumab deruxtecan (T-DXd) （10mg/kg,静脉注射）治疗EMT6-hHER2 肿瘤小鼠，观察小鼠体内肿瘤变化情况。
结果:Trastuzumab deruxtecan 在治疗后 18 天显着抑制EMT6-hHER2 肿瘤小鼠体内肿瘤的生长。[1]

Immobilized Human ERBB2 / HER2 / CD340, His Tag at 2 μg/mL (30 μL/well) can bind trastuzumab
deruxtecan, with the EC50 is 0.04980 μg/mL.